GB201504675D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB201504675D0 GB201504675D0 GBGB1504675.8A GB201504675A GB201504675D0 GB 201504675 D0 GB201504675 D0 GB 201504675D0 GB 201504675 A GB201504675 A GB 201504675A GB 201504675 D0 GB201504675 D0 GB 201504675D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504675.8A GB201504675D0 (en) | 2015-03-19 | 2015-03-19 | Pharmaceutical compounds |
| EP16713022.8A EP3271358B1 (en) | 2015-03-19 | 2016-03-21 | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor |
| CA2979009A CA2979009C (en) | 2015-03-19 | 2016-03-21 | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor |
| JP2017549261A JP6675415B2 (ja) | 2015-03-19 | 2016-03-21 | ムスカリンｍ１受容体及び／またはｍ４受容体のアゴニストとしてのスピロ環状化合物 |
| US15/559,375 US10167284B2 (en) | 2015-03-19 | 2016-03-21 | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor |
| ES16713022T ES2852753T3 (es) | 2015-03-19 | 2016-03-21 | Compuestos espirocíclicos como agonistas del receptor muscarínico M1 y/o M4 |
| PCT/GB2016/050771 WO2016147011A1 (en) | 2015-03-19 | 2016-03-21 | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor |
| CN201680016714.9A CN107406449B (zh) | 2015-03-19 | 2016-03-21 | 作为毒蕈碱m1受体和/或m4受体的激动剂的螺环化合物 |
| AU2016231951A AU2016231951B9 (en) | 2015-03-19 | 2016-03-21 | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor |
| DK16713022.8T DK3271358T3 (da) | 2015-03-19 | 2016-03-21 | Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor |
| HK18107567.8A HK1248218A1 (zh) | 2015-03-19 | 2018-06-11 | 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504675.8A GB201504675D0 (en) | 2015-03-19 | 2015-03-19 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201504675D0 true GB201504675D0 (en) | 2015-05-06 |
Family
ID=53052080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1504675.8A Ceased GB201504675D0 (en) | 2015-03-19 | 2015-03-19 | Pharmaceutical compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10167284B2 (ja) |
| EP (1) | EP3271358B1 (ja) |
| JP (1) | JP6675415B2 (ja) |
| CN (1) | CN107406449B (ja) |
| AU (1) | AU2016231951B9 (ja) |
| CA (1) | CA2979009C (ja) |
| DK (1) | DK3271358T3 (ja) |
| ES (1) | ES2852753T3 (ja) |
| GB (1) | GB201504675D0 (ja) |
| HK (1) | HK1248218A1 (ja) |
| WO (1) | WO2016147011A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402405QA (en) | 2011-11-18 | 2014-09-26 | Heptares Therapeutics Ltd | Muscarinic m1 receptor agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP4219464A1 (en) | 2018-03-23 | 2023-08-02 | Pfizer Inc. | Piperazine azaspiro derivaves |
| GB201810239D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PE20221453A1 (es) | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
| WO2021070091A1 (en) | 2019-10-09 | 2021-04-15 | Novartis Ag | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2206699A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO2007076070A2 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| CN102361876B (zh) * | 2009-01-26 | 2015-02-04 | 以色列生物研究所 | 二环杂环螺环化合物 |
| SG11201402405QA (en) * | 2011-11-18 | 2014-09-26 | Heptares Therapeutics Ltd | Muscarinic m1 receptor agonists |
| DK2897948T3 (en) * | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2015
- 2015-03-19 GB GBGB1504675.8A patent/GB201504675D0/en not_active Ceased
-
2016
- 2016-03-21 DK DK16713022.8T patent/DK3271358T3/da active
- 2016-03-21 CN CN201680016714.9A patent/CN107406449B/zh active Active
- 2016-03-21 EP EP16713022.8A patent/EP3271358B1/en active Active
- 2016-03-21 AU AU2016231951A patent/AU2016231951B9/en active Active
- 2016-03-21 ES ES16713022T patent/ES2852753T3/es active Active
- 2016-03-21 US US15/559,375 patent/US10167284B2/en active Active
- 2016-03-21 JP JP2017549261A patent/JP6675415B2/ja not_active Expired - Fee Related
- 2016-03-21 WO PCT/GB2016/050771 patent/WO2016147011A1/en active Application Filing
- 2016-03-21 CA CA2979009A patent/CA2979009C/en active Active
-
2018
- 2018-06-11 HK HK18107567.8A patent/HK1248218A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016231951B9 (en) | 2020-04-16 |
| CN107406449B (zh) | 2020-11-10 |
| DK3271358T3 (da) | 2021-02-08 |
| US20180072727A1 (en) | 2018-03-15 |
| AU2016231951A1 (en) | 2017-09-28 |
| AU2016231951B2 (en) | 2020-04-09 |
| HK1248218A1 (zh) | 2018-10-12 |
| US10167284B2 (en) | 2019-01-01 |
| EP3271358B1 (en) | 2020-11-18 |
| CA2979009C (en) | 2023-09-12 |
| JP2018508562A (ja) | 2018-03-29 |
| EP3271358A1 (en) | 2018-01-24 |
| JP6675415B2 (ja) | 2020-04-01 |
| CN107406449A (zh) | 2017-11-28 |
| ES2852753T3 (es) | 2021-09-14 |
| CA2979009A1 (en) | 2016-09-22 |
| WO2016147011A1 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266017A (en) | Pharmaceutical compounds | |
| IL258213A (en) | Pharmaceutical compounds | |
| GB201612092D0 (en) | Pharmaceutical compounds | |
| GB201511790D0 (en) | Pharmaceutical compound | |
| GB201617758D0 (en) | Pharmaceutical compounds | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| IL258246A (en) | Pharmaceutical compounds | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| GB201519352D0 (en) | Pharmaceutical compounds | |
| ZA201900540B (en) | Pharmaceutical compounds | |
| HUE052107T2 (hu) | Gyógyszerészeti vegyületek | |
| GB201612095D0 (en) | Pharmaceutical compounds | |
| GB201617454D0 (en) | Pharmaceutical compounds | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| GB201516411D0 (en) | Pharmaceutical compound | |
| GB201617871D0 (en) | Pharmaceutical compounds | |
| SG11201708818VA (en) | Pharmaceutical compound | |
| ZA201904033B (en) | Pharmaceutical compounds | |
| HK1226067B (zh) | 藥物化合物 | |
| GB201614037D0 (en) | Pharmaceutical compounds | |
| SG11201708817XA (en) | Pharmaceutical compound | |
| GB201517451D0 (en) | Pharmaceutical compounds | |
| GB201602871D0 (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |